Truist Securities stays Buy on Terns Pharmaceuticals (TERN) as Merck acquires 'for a steal'

March 25, 2026 8:12 AM

Truist Securities analyst Srikripa Devarakonda reiterated a Buy rating and $56.00 price target on Terns Pharmaceuticals (NASDAQ: TERN)The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found